FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W62862726> ?p ?o ?g. }

• W62862726 endingPage "45" @default.
• W62862726 startingPage "35" @default.
• W62862726 abstract "Albumin-interferon-α (IFN-α) is a novel 85.7–kDa recombinant protein consisting of IFN-α that is genetically fused to human serum albumin. In this Phase I/II, multicentre, open-label study, we evaluated the safety and tolerability, pharmacokinetics and pharmacodynamics of albumin-IFN-α in IFN-α-experienced patients with chronic hepatitis C. Albumin-IFN-α was administered in 22 escalating doses (7–900 μg) in a single injection or in two injections 14 days apart. In the 119 patients studied, there were no discontinuations because of adverse events, and albumin-IFN-α had a favourable safety profile at doses up to 900 μg. The most common adverse events were headache (56%), fatigue (52%), injection site erythema (38%), arthralgias (32%) and pyrexia (27%). Reduced clearance resulted in a mean elimination half-life of 159h, which supports dosing at 2- to 4-week intervals. Induction of the IFN-specific gene OAS1 was maintained for ≥28 days following a single injection of albumin-IFN-α at doses of ≥40 μg. Dose-dependent antiviral activity was observed in this IFN-α-experienced study population. Antiviral activity of ≥1.0–log reductions in HCV RNA was observed in 47% (37/78) of patients in the 120- to 900-μg cohorts and in 59% (16/27) in the 400- to 900-μg double-injection cohorts. These results support further clinical studies of albumin-IFN-α for the treatment of patients with chronic hepatitis C." @default.
• W62862726 created "2016-06-24" @default.
• W62862726 creator A5005876143 @default.
• W62862726 creator A5015778932 @default.
• W62862726 creator A5030789303 @default.
• W62862726 creator A5037393232 @default.
• W62862726 creator A5041256978 @default.
• W62862726 creator A5050486969 @default.
• W62862726 creator A5054201295 @default.
• W62862726 creator A5056557259 @default.
• W62862726 creator A5066737700 @default.
• W62862726 creator A5067953805 @default.
• W62862726 creator A5072944023 @default.
• W62862726 creator A5074779832 @default.
• W62862726 creator A5076691315 @default.
• W62862726 creator A5088683463 @default.
• W62862726 date "2006-01-01" @default.
• W62862726 modified "2023-10-17" @default.
• W62862726 title "A Phase I/II Study Evaluating Escalating Doses of Recombinant Human Albumin-Interferon-α Fusion Protein in Chronic Hepatitis C Patients who have Failed Previous Interferon-α-Based Therapy" @default.
• W62862726 cites W2004907392 @default.
• W62862726 cites W2027545702 @default.
• W62862726 cites W2036457685 @default.
• W62862726 cites W2043519223 @default.
• W62862726 cites W2120696122 @default.
• W62862726 cites W2127685726 @default.
• W62862726 cites W2142337801 @default.
• W62862726 cites W2144580269 @default.
• W62862726 cites W2175739361 @default.
• W62862726 cites W2405432308 @default.
• W62862726 cites W4232534952 @default.
• W62862726 cites W55697788 @default.
• W62862726 doi "https://doi.org/10.1177/135965350601100111" @default.
• W62862726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16518958" @default.
• W62862726 hasPublicationYear "2006" @default.
• W62862726 type Work @default.
• W62862726 sameAs 62862726 @default.
• W62862726 citedByCount "45" @default.
• W62862726 countsByYear W628627262012 @default.
• W62862726 countsByYear W628627262013 @default.
• W62862726 countsByYear W628627262014 @default.
• W62862726 countsByYear W628627262016 @default.
• W62862726 countsByYear W628627262020 @default.
• W62862726 countsByYear W628627262021 @default.
• W62862726 crossrefType "journal-article" @default.
• W62862726 hasAuthorship W62862726A5005876143 @default.
• W62862726 hasAuthorship W62862726A5015778932 @default.
• W62862726 hasAuthorship W62862726A5030789303 @default.
• W62862726 hasAuthorship W62862726A5037393232 @default.
• W62862726 hasAuthorship W62862726A5041256978 @default.
• W62862726 hasAuthorship W62862726A5050486969 @default.
• W62862726 hasAuthorship W62862726A5054201295 @default.
• W62862726 hasAuthorship W62862726A5056557259 @default.
• W62862726 hasAuthorship W62862726A5066737700 @default.
• W62862726 hasAuthorship W62862726A5067953805 @default.
• W62862726 hasAuthorship W62862726A5072944023 @default.
• W62862726 hasAuthorship W62862726A5074779832 @default.
• W62862726 hasAuthorship W62862726A5076691315 @default.
• W62862726 hasAuthorship W62862726A5088683463 @default.
• W62862726 hasBestOaLocation W628627261 @default.
• W62862726 hasConcept C111113717 @default.
• W62862726 hasConcept C112705442 @default.
• W62862726 hasConcept C126322002 @default.
• W62862726 hasConcept C165616093 @default.
• W62862726 hasConcept C197934379 @default.
• W62862726 hasConcept C203014093 @default.
• W62862726 hasConcept C2776125364 @default.
• W62862726 hasConcept C2776178377 @default.
• W62862726 hasConcept C2776455275 @default.
• W62862726 hasConcept C2777288759 @default.
• W62862726 hasConcept C2778375690 @default.
• W62862726 hasConcept C2908647359 @default.
• W62862726 hasConcept C71924100 @default.
• W62862726 hasConcept C90924648 @default.
• W62862726 hasConcept C98274493 @default.
• W62862726 hasConcept C99454951 @default.
• W62862726 hasConceptScore W62862726C111113717 @default.
• W62862726 hasConceptScore W62862726C112705442 @default.
• W62862726 hasConceptScore W62862726C126322002 @default.
• W62862726 hasConceptScore W62862726C165616093 @default.
• W62862726 hasConceptScore W62862726C197934379 @default.
• W62862726 hasConceptScore W62862726C203014093 @default.
• W62862726 hasConceptScore W62862726C2776125364 @default.
• W62862726 hasConceptScore W62862726C2776178377 @default.
• W62862726 hasConceptScore W62862726C2776455275 @default.
• W62862726 hasConceptScore W62862726C2777288759 @default.
• W62862726 hasConceptScore W62862726C2778375690 @default.
• W62862726 hasConceptScore W62862726C2908647359 @default.
• W62862726 hasConceptScore W62862726C71924100 @default.
• W62862726 hasConceptScore W62862726C90924648 @default.
• W62862726 hasConceptScore W62862726C98274493 @default.
• W62862726 hasConceptScore W62862726C99454951 @default.
• W62862726 hasIssue "1" @default.
• W62862726 hasLocation W628627261 @default.
• W62862726 hasLocation W628627262 @default.
• W62862726 hasOpenAccess W62862726 @default.
• W62862726 hasPrimaryLocation W628627261 @default.
• W62862726 hasRelatedWork W1736016875 @default.
• W62862726 hasRelatedWork W1822154343 @default.

• next